Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
GENFIT's revenue halves in Q3 2016
November 8, 2016 Off

GENFIT's revenue halves in Q3 2016

By Dino Mustafić

GENFIT has today announced its cash and cash equivalents as at September 30, 2016

Esperite's revenue slightly lifted in Q3 compared to same period last year
November 8, 2016 Off

Esperite's revenue slightly lifted in Q3 compared to same period last year

By Dino Mustafić

The Ducth pharmaceutical company Esperite N.V. has announced today that cumulative consolidated revenue increased

After $195 million in talc verdicts, J&J strives to change court
November 8, 2016 Off

After $195 million in talc verdicts, J&J strives to change court

By Dino Mustafić

After a $67.5 million jury verdict against Johnson & Johnson…

November 8, 2016 Off

DBV Technologies closes down phase II study of Viaskin Milk

By Dino Mustafić

DBV Technologies has completed the enrollment for Part B, or Phase II, of the Phase I/II study of Viaskin Milk

November 8, 2016 Off

BRIEF: Advanced Oncotherpay appoints new broker

By Dino Mustafić

BRIEF: Advanced Oncotherpay appoints new broker

November 7, 2016 Off

Testing investigational Zika vaccine candidate in humans

By Dino Mustafić

The first of five early stage clinical trials to test the safety and ability of an investigational Zika vaccine

November 7, 2016 Off

Bayer seeks approval for its liver cancer drug

By Dino Mustafić

Bayer on Monday announced the submission of applications to extend the marketing authorization for its oral multi-kinase inhibitor

Vertex's Phase 3 cystic fibrosis drug study shows improvement
November 7, 2016 Off

Vertex's Phase 3 cystic fibrosis drug study shows improvement

By Dino Mustafić

Vertex Pharmaceuticals Incorporated today announced the results of a Phase 3 study of Orkambi (lumacaftor/ivacaftor) in children with cystic fibrosis…

Orphan drugs make 35% Horizon's sale in Q3 2016
November 7, 2016 Off

Orphan drugs make 35% Horizon's sale in Q3 2016

By Dino Mustafić

Horizon Pharma has announced its third-quarter 2016 financial results on Monday.

Neovacs enroles first U.S. patient in its Phase IIb study of IFNalpha Kinoid in lupus.
November 7, 2016 Off

Neovacs enroles first U.S. patient in its Phase IIb study of IFNalpha Kinoid in lupus.

By Dino Mustafić

Neovacs, a player in active immunotherapy for the treatment of autoimmune diseases, has enroled the first U.S. patient in its international Phase IIb clinical study of IFNalpha Kinoid in lupus.

Posts pagination

Previous 1 … 3,549 3,550 3,551 … 3,605 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine